Floatz logo

Cediranib

Head and Neck Cancer

National Cancer Institute (NCI)Small moleculePhase 2Active
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
73/ 100

Competitive context

113 Active assets in the Head and Neck Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
ImmunityBio, Inc.
Phase 3BB
Carboplatin
Rapa Therapeutics LLC
Phase 3BB
Pembrolizumab
Thomas Jefferson University
Phase 3BB
Cyclophosphamide
Zelluna Immunotherapy AS
Phase 3BB
FILGRASTIM
University of Colorado, Denver
Phase 2BB

View all 50 →

Same molecule, other indications

Cediranib is also rated in:

gliosarcomaDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent NeuroblastomaDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Colon CancerDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →